Clostridium difficile infection is commonly associated with antibiotic treatment and is one of the most common nosocomial infections.
Symptoms usually start on days 4-9 of antibiotic treatment, but may also occur up to 8-10 weeks after discontinuation of antibiotics.
Discontinuation of antibiotics may be the only measure needed for patients with only mild diarrhea, no fever, no abdominal pain nor a high WBC count.
Cessation of antibiotics allows for reconstitution of the normal colonic microflora and markedly reduces risk of relapse.
A pseudomembrane-driven faecal microbiota transplantation protocol comprising multiple faecal infusions and concomitant vancomycin proves to be more effective than a single faecal transplant followed by vancomycin for treating severe Clostridium difficile infection (CDI) refractory to antibiotics, a study has shown.
Use of oral capsules in the delivery of faecal microbiota transplantation (FMT) appears to be equally effective as colonoscopy in terms of preventing recurrent Clostridium difficile infection (RCDI) over 12 weeks, according to the results of a trial.
Elderly patients with Clostridium difficile (C. difficile) infection who were given extended-pulsed fidaxomicin were more likely to have sustained clinical cure a month after treatment than those on standard-dose vancomycin, results of the phase 3b/4 EXTEND* trial show.
The risk of Clostridium difficile infection (CDI) in hospitalized patients may be halved by a strategy of administering probiotics within 2 days of antibiotic initiation, according to the results of a systematic review.
Bezlotoxumab, a human monoclonal antibody against Clostridium difficile (C. difficile) toxin B, appears to reduce the risk of recurrent C. difficile infection, according to findings from the MODIFY I* and MODIFY II** trials.
Foecal microbiota transplantation (FMT) done through the lower gastrointestinal (LGI) delivery route appears to be the most effective way for the prevention of recurrence/relapse of Clostridium difficile infection (CDI), suggests a study.
Transfer of sterile filtrates, rather than faecal microbiota, from donor stool may be enough to restore normal stool habits and eliminate symptoms in patients with Clostridium difficile infection (CDI), according to a study.
New drug applications approved by US FDA as of 16 - 31 October 2016 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
A new technology involving the use of monocyte-derived hepatocyte-like (MH) cells has demonstrated high sensitivity and specificity in the diagnosis of idiosyncratic drug-induced liver injury (DILI), data presented at the Asian Pacific Digestive Week (APDW) 2017 held in Hong Kong have shown.